Skip to content
Free tracked delivery • Secure checkout
retatrutideconnect.com
0 Buy now
Retatrutide 10 mg 2 mg x 5 vials product image Sale
✓Batch Documentation
✓Tracked Shipping
✓Secure Checkout
✓Research Use Only
WHY THIS FORMAT

Retatrutide 10 mg in 5 Separate 2 mg Vials

🧪 → 5 × 2 mg

Multi-Vial Research Format

Five individually presented 2 mg vials keep the 10 mg kit divided into separate research units rather than one larger vial.

🧬 → 3 PATHWAYS

Triple-Agonist Research Compound

Retatrutide (LY3437943) is being studied for activity at GIP, GLP-1 and glucagon receptors, which distinguishes it from single- and dual-agonist compounds.

📄 → TRACE

Batch Identification & Documentation

Product identification and available batch documentation provide a clearer record of the supplied research material.

WHAT IS IT?

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly and studied as a triple agonist acting at the GIP, GLP-1 and glucagon receptors.

It remains an investigational compound and is not currently approved by the FDA or other regulatory agencies as a medicine. Lilly continues to evaluate retatrutide through its clinical development program.

The product presented here is a 10 mg multi-vial research format containing five separate 2 mg vials and is presented for laboratory research purposes.

Retatrutide 10 mg 2 mg x 5 vials alternate product image
Retatrutide 10 mg for sale packaging with 5 x 2 mg vials
RESEARCH CONTEXT

Why Retatrutide Is Drawing Research Interest

Retatrutide has attracted significant scientific attention because its mechanism combines activity at three metabolic hormone receptors: GIP, GLP-1 and glucagon.

Lilly is evaluating the compound in Phase 3 clinical trials, while published and announced studies continue to expand the available evidence around its metabolic effects and safety profile. Retatrutide remains investigational, and clinical-trial findings should not be interpreted as approval for general medical use.

Our Research section follows the developing evidence, regulatory status and major trial readouts with links to original sources wherever possible.

Choose your offer →
PRODUCT DETAILS

Retatrutide 10 mg Research Kit — 5 × 2 mg Vials

Retatrutide 10 mg is a research peptide presented as 5 separate vials at 2 mg each, giving a total content of 10 mg per pack. Its multi-vial format makes it a practical choice for controlled handling, flexible allocation, and consistent storage in research settings.

Retatrutide is widely discussed in scientific literature as a triple receptor agonist that acts on GLP-1, GIP, and glucagon pathways. Current studies describe it as an investigational compound of interest in metabolic research, especially in areas related to body weight, glucose regulation, and energy balance.pmc.ncbi.nlm.nih+2

This product is intended for research purposes only and is not marketed as a substitute for any approved medication or treatment. For a modern product page, pairing this description with clear format details, usage context, and compliance language will usually perform better than heavy clinical claims.

Product Specifications

Research identifier

LY3437943
Format

Multi-vial research kit
Quantity

5 vials
Stated content per vial

2 mg
Total stated content

10 mg
Intended purpose

Laboratory research only
CUSTOMER REVIEWS

Customer reviews

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

FAQ

Questions before checkout?

Answer the final questions that might otherwise stop a purchase.

What is retatrutide?

Retatrutide, also known by the research identifier LY3437943, is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors. It is being developed by Eli Lilly and remains under clinical investigation.

Is retatrutide FDA approved?

No. Retatrutide is not currently FDA approved. Lilly describes it as an investigational medication undergoing clinical development.

What does the 10 mg kit contain?

The product format shown on this page contains five separate vials with a stated content of 2 mg each, giving 10 mg total stated content per pack.

Is retatrutide the same as tirzepatide?

No. They are different compounds. Tirzepatide acts at GIP and GLP-1 receptors, whereas retatrutide is being studied as a triple agonist involving GIP, GLP-1 and glucagon receptors.

What does “triple agonist” mean?

In retatrutide research, “triple agonist” refers to activity involving three receptor pathways: GIP, GLP-1 and glucagon. Lilly uses this terminology when describing the compound's mechanism.

Is batch documentation available?

Available product and batch documentation should be reviewed for the specific lot supplied. Documentation availability can vary by batch.

Where can I follow new retatrutide research?

Our Research & Articles section follows major clinical-trial developments, regulatory updates and published findings, with emphasis on original sources and clearly dated information.

RESEARCH & UPDATES

Latest Retatrutide Research & Articles

Follow clinical-trial results, regulatory developments and explainers covering retatrutide, its triple-agonist mechanism and the evolving research landscape.

View All Articles
PRODUCT INFORMATION

Review the Retatrutide 10 mg Research Kit

View the product format, available documentation and ordering information for the 5 × 2 mg research presentation.

Original price was: $179,00.Current price is: $149,00.
Request Documentation
Retatrutide 10 mg Original price was: $179,00.Current price is: $149,00.
Buy now